[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,481,581
  • Shares Outstanding, K 33,786
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -135 M
  • EBITDA $ -134 M
  • 60-Month Beta 1.14
  • Price/Sales 44.71
  • Price/Cash Flow N/A
  • Price/Book 4.28

Options Overview Details

View History
  • Implied Volatility 64.72% (-4.96%)
  • Historical Volatility 54.41%
  • IV Percentile 12%
  • IV Rank 10.67%
  • IV High 164.90% on 12/10/25
  • IV Low 52.76% on 05/15/26
  • Expected Move (DTE 14) 3.87 (5.22%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 536
  • Volume Avg (30-Day) 895
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 39,402
  • Open Int (30-Day) 39,698
  • Expected Range 70.17 to 77.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.94
  • Number of Estimates 6
  • High Estimate $-1.22
  • Low Estimate $-2.47
  • Prior Year $-2.78
  • Growth Rate Est. (year over year) +30.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.24 +15.71%
on 07/21/26
75.77 -1.90%
on 07/08/26
-0.57 (-0.76%)
since 07/07/26
3-Month
54.13 +37.32%
on 06/09/26
84.94 -12.49%
on 05/08/26
-9.04 (-10.84%)
since 05/07/26
52-Week
22.01 +237.71%
on 08/08/25
109.00 -31.81%
on 04/20/26
+52.58 (+241.75%)
since 08/07/25

Most Recent Stories

More News
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

SAN FRANCISCO , July 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026, after...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , July 24, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on July 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Two global registrational Phase 3 trials initiated in ZENITH AD program

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO , June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

SAN FRANCISCO , May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare...

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Q1 Earnings Call Highlights

Nektar Therapeutics (NASDAQ:NKTR) outlined plans to advance its lead regulatory T-cell (Treg) therapy rezpegaldesleukin (REZPEG) into late-stage development, while also reporting first-quarter 2026 financial...

NKTR : 75.81 (+3.21%)
Nektar: Q1 Earnings Snapshot

Nektar: Q1 Earnings Snapshot

NKTR : 75.81 (+3.21%)
Nektar Therapeutics Reports First Quarter 2026 Financial Results

SAN FRANCISCO , May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2026.

NKTR : 75.81 (+3.21%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The...

NKTR : 75.81 (+3.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 76.07
2nd Resistance Point 75.13
1st Resistance Point 74.29
Last Price 75.81
1st Support Level 72.51
2nd Support Level 71.57
3rd Support Level 70.73

See More

52-Week High 109.00
Last Price 75.81
Fibonacci 61.8% 75.77
Fibonacci 50% 65.50
Fibonacci 38.2% 55.24
52-Week Low 22.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.